Gilead Builds Adherence Trial and Behavior Profiling Data Into Truvada PrEP Approval
This article was originally published in RPM Report
Executive Summary
FDA approval of Gilead’s Truvada for pre-exposure prophylaxis generated national news in advance of the major HIV/AIDS international scientific meeting starting in Washington one week later. As part of the final negotiations to get the approval done in time for the news window, FDA and Gilead worked out an interesting arrangement on post-marketing studies that has broad implications for future sponsors.
You may also be interested in...
An Emerging REMS Dilemma: Qnexa, Truvada – and Korlym
Two high-profile applications pose a thorny dilemma for FDA: how to impose a REMS for a new indication without restricting access for already approved uses where restrictions are not appropriate. That same issue didn’t seem to slow the agency down on a recent approval decision involving a very controversial ingredient.
When Interests Align: Medication Adherence
When you think about the impact of the Food & Drug Administration’s focus on real-world drug safety, the disruptive implications of the Affordable Care Act, and the relentless pressure to find savings in health care, it is easy to see the dangers posed to biopharma companies. But those forces aren’t all negative. In fact, they are helping to mobilize government, consumer groups and payors to push hard on at least one decidedly pro-pharma agenda: improving adherence with prescription medicines.
"A Really Exciting Place to Work": An Interview With FDA's Top Antiviral Drug Reviewer
Division of Antivirals Director Debra Birnkrant talks HIV, HCV, influenza, smallpox and more with The RPM Report.